TY - JOUR
T1 - FDA-Approved Medications to Treat Tardive Dyskinesia
AU - McEvoy, Joseph P.
PY - 2019/12/17
Y1 - 2019/12/17
N2 - Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.
AB - Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.
UR - http://www.scopus.com/inward/record.url?scp=85076977070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076977070&partnerID=8YFLogxK
U2 - 10.4088/JCP.NU18041BR3C
DO - 10.4088/JCP.NU18041BR3C
M3 - Review article
C2 - 31851437
AN - SCOPUS:85076977070
SN - 0160-6689
VL - 81
JO - The Journal of clinical psychiatry
JF - The Journal of clinical psychiatry
IS - 1
ER -